USC transfer RB Markese Stepp, if healthy, can take pressure off Adrian Martinez. That's especially critical this season.
Search / 90855 results found Showing: 1-10 of 90855
Western Michigan’s Rachel Bontrager, a Valparaiso graduate, was named the MAC Player of the Year. The senior had 387 kills, which was fourth overall among NCAA Division I players.
CNN's Jim Acosta talks with Dr. Jonathan Reiner of George Washington University about the coronavirus surge Michigan is experiencing, and Texa…
Western Michigan’s Rachel Bontrager, a Valparaiso graduate, was named the MAC Player of the Year. The senior finished the season with 387 kill…
Chloe Zhao dedicated 'Nomadland's Best Film win at the EE BAFTA Film Awards to the nomadic community on Sunday night (11.04.21).
Grandmother shot, killed in Boston, while sitting on front porch Saturday
Tony Evans Jr. had signed with the Cowboys in February.
CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) program are being reported at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021. The presentations focus on registrational PATHFINDER trial data of AYVAKIT™ (avapritinib) in advanced SM, PIONEER Part 1 data highlighting the impact of AYVAKIT on skin manifestations of SM, and Phase 1 trial data for BLU-263, a next-generation KIT D816V inhibitor. Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in non-advanced SM and other mast cell disorders.
Commented